Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Kenjiro Okada

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8860-1123; OpenAlex author ID A5086631961. Sources: OpenAlex.

Their work

Papers
31
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 6 papers · 2022: 7 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 5 papers

Papers 31

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Independent Prognostic Value of Natural Tooth Count Versus Posterior Teeth Occlusion in Resected Pancreatic Cancer. Co-author DOI 10.1002/jhbp.70113↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  6. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  7. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  8. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Co-author DOI 10.1002/jhbp.1412↗
  9. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  10. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-03009-w↗
  11. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  12. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Co-author DOI 10.1007/s12328-022-01741-2↗
  13. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.10.019↗
  14. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Co-author DOI 10.1002/jhbp.1151↗
  15. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  16. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Co-author DOI 10.1007/s12328-022-01621-9↗
  17. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.12.009↗
  18. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Co-author DOI 10.1016/j.pan.2022.03.018↗
  19. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2022.04.004↗
  20. Prognostic impact of postoperative infection in patients with pancreatic cancer: A multicenter cohort study. Co-author DOI 10.1016/j.surg.2022.09.002↗
  21. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Co-author DOI 10.1007/s00423-020-02025-4↗
  22. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Co-author DOI 10.1007/s11605-021-04978-3↗
  23. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  24. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  25. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Co-author DOI 10.1159/000520064↗
  26. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09278-9↗
  27. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. Co-author DOI 10.1002/jhbp.687↗
  28. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Co-author DOI 10.1002/jhbp.737↗
  29. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Co-author DOI 10.1007/s00423-020-01914-y↗
  30. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.019↗
  31. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. Co-author DOI 10.1002/jso.25066↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 31 shared papers, 2018–2026 · strength 5.09
  2. Yoshiaki Murakami · 23 shared papers, 2018–2026 · strength 3.67
  3. Shin’ya Takahashi · 24 shared papers, 2018–2025 · strength 3.63
  4. Tatsuaki Sumiyoshi · 21 shared papers, 2020–2026 · strength 3.61
  5. Naru Kondo · 18 shared papers, 2018–2024 · strength 2.48
  6. Hiroyuki Otsuka · 17 shared papers, 2020–2023 · strength 2.44
  7. Ryuta Shintakuya · 10 shared papers, 2023–2026 · strength 2.15
  8. Yasutaka Ishii · 8 shared papers, 2021–2026 · strength 1.49
  9. Takumi Harada · 5 shared papers, 2023–2026 · strength 1.11
  10. Masamichi Mizuma · 5 shared papers, 2022–2026 · strength 0.90
  11. Kenta Baba · 4 shared papers, 2023–2025 · strength 0.81
  12. Sohei Satoi · 4 shared papers, 2025–2026 · strength 0.78
  13. Daisuke Hashimoto · 4 shared papers, 2025–2026 · strength 0.78
  14. Satoshi Hirano · 4 shared papers, 2025–2026 · strength 0.78
  15. So Yamaki · 3 shared papers, 2025–2026 · strength 0.60
  16. Teiichi Sugiura · 3 shared papers, 2025–2026 · strength 0.60
  17. Atsushi Oba · 3 shared papers, 2025–2026 · strength 0.60
  18. Katsuhisa Ohgi · 3 shared papers, 2025–2026 · strength 0.60
  19. Koetsu Inoue · 3 shared papers, 2025–2026 · strength 0.60
  20. Fuyuhiko Motoi · 3 shared papers, 2025–2026 · strength 0.60
  21. Yosuke Inoue · 3 shared papers, 2026 · strength 0.59
  22. Michiaki Unno · 3 shared papers, 2026 · strength 0.59
  23. Shiro Oka · 2 shared papers, 2025–2026 · strength 0.51
  24. Tomofumi Tsuboi · 3 shared papers, 2021–2023 · strength 0.43
  25. Daisuke Ban · 2 shared papers, 2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.